Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
Functional Assessment of Cancer Therapy Kidney Symptom Index-19
health care survey
health-related quality of life
patient-reported outcomes
renal cell carcinoma
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 06 2023
02 06 2023
Historique:
received:
08
12
2022
accepted:
06
01
2023
medline:
8
6
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
There is a lack of consensus regarding the optimal method of assessing health-related quality of life (HR-QOL) among patients with metastatic renal cell carcinoma (mRCC). This study explored the perceived relevance of items that make up the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (FKSI-19), as judged by patients with mRCC. This was a multinational cross-sectional survey. Eligible patients responded to a questionnaire composed of 18 items that assessed the perceived relevance of each item in the FKSI-19 questionnaire. Open-ended questions assessed additional issues deemed relevant by patients. Responses were grouped as relevant (scores 2-5) or nonrelevant (score 1). Descriptive statistics were collated, and open-ended questions were analyzed and categorized into descriptive categories. Spearman correlation statistics were used to test the association between relevance and clinical characteristics. A total of 151 patients were included (gender: 78.1 M, 21.9F; median age: 64; treatment: 38.4 immunotherapy, 29.8 targeted therapy, 13.9 immuno-TKI combination therapy) in the study. The most relevant questions evaluated fatigue (77.5), lack of energy (72.2), and worry that their condition will get worse (71.5). Most patients rated blood in urine (15.2), fevers (16.6), and lack of appetite (23.2) as least relevant. Qualitative analysis of open-ended questions revealed several themes, including emotional and physical symptoms, ability to live independently, effectiveness of treatment, family, spirituality, and financial toxicity. There is a need to refine widely used HR-QOL measures that are employed among patients diagnosed with mRCC treated with contemporary therapies. Guidance was provided for the inclusion of more relevant items to patients' cancer journey.
Sections du résumé
BACKGROUND
There is a lack of consensus regarding the optimal method of assessing health-related quality of life (HR-QOL) among patients with metastatic renal cell carcinoma (mRCC). This study explored the perceived relevance of items that make up the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (FKSI-19), as judged by patients with mRCC.
METHODS
This was a multinational cross-sectional survey. Eligible patients responded to a questionnaire composed of 18 items that assessed the perceived relevance of each item in the FKSI-19 questionnaire. Open-ended questions assessed additional issues deemed relevant by patients. Responses were grouped as relevant (scores 2-5) or nonrelevant (score 1). Descriptive statistics were collated, and open-ended questions were analyzed and categorized into descriptive categories. Spearman correlation statistics were used to test the association between relevance and clinical characteristics.
RESULTS
A total of 151 patients were included (gender: 78.1 M, 21.9F; median age: 64; treatment: 38.4 immunotherapy, 29.8 targeted therapy, 13.9 immuno-TKI combination therapy) in the study. The most relevant questions evaluated fatigue (77.5), lack of energy (72.2), and worry that their condition will get worse (71.5). Most patients rated blood in urine (15.2), fevers (16.6), and lack of appetite (23.2) as least relevant. Qualitative analysis of open-ended questions revealed several themes, including emotional and physical symptoms, ability to live independently, effectiveness of treatment, family, spirituality, and financial toxicity.
CONCLUSION
There is a need to refine widely used HR-QOL measures that are employed among patients diagnosed with mRCC treated with contemporary therapies. Guidance was provided for the inclusion of more relevant items to patients' cancer journey.
Identifiants
pubmed: 36917626
pii: 7077455
doi: 10.1093/oncolo/oyad028
pmc: PMC10243758
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
494-500Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
J Support Oncol. 2006 Apr;4(4):191-9
pubmed: 16669463
Qual Life Res. 2021 Sep;30(9):2663-2670
pubmed: 33846957
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Immunother Cancer. 2019 Mar 12;7(1):71
pubmed: 30867071
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Eur Urol. 2022 Oct;82(4):427-439
pubmed: 35843776
Clin Cancer Res. 2016 Apr 1;22(7):1553-8
pubmed: 26758559
Eur Urol Focus. 2020 Jan 15;6(1):26-30
pubmed: 30858072
Lancet Oncol. 2018 Jun;19(6):e317-e326
pubmed: 29893263
Lancet Oncol. 2022 Feb;23(2):292-303
pubmed: 35032437